-
IMPACT OF MEDICARE PRICE NEGOTIATION ON COMPARATIVE COST-EFFECTIVENESS OF IBRUTINIB, ACALABRUTINIB, AND ZANUBRUTINIB IN CHRONIC LYMPHOCYTIC LEUKEMIA: A SYSTEMATIC REVIEW AND NETWORK META-ANALYSIS
Aug 11, 2026, 17:16 PM -
SOCIOECONOMIC BURDEN OF ATHEROSCLEROTIC CARDIOVASCULAR DISEASE IN SPAIN: WHEN CHRONIC KIDNEY DISEASE AND INFLAMMATORY RISK CO-OCCUR
Aug 11, 2026, 17:16 PM -
OVERALL SURVIVAL OF SUGEMALIMAB PLUS CHEMOTHERAPY VERSUS FIRST-LINE PD-1/PD-L1 INHIBITOR REGIMENS IN METASTATIC NSCLC: AN ETHNICITY-ADJUSTED INDIRECT TREATMENT COMPARISON
Aug 11, 2026, 17:16 PM -
TIME TO ACCESS FOR INNOVATIVE MEDICINES IN GREECE: A RETROSPECTIVE ANALYSIS OF PUBLIC DATA IN 2024- 2025
Aug 11, 2026, 17:16 PM -
WAITING FOR EVIDENCE OR EARLIER ACCESS? PREFERENCES FOR ONE-TIME THERAPIES AMONG CANCER PATIENTS AND THE GENERAL PUBLIC
Aug 11, 2026, 17:16 PM -
EARLY ECONOMIC AND PATHWAY IMPACT OF INCORPORATING NOVEL MASS SPECTROMETRY-BASED TESTING INTO TREATMENT RESPONSE ASSESSMENT FOR MULTIPLE MYELOMA
Aug 11, 2026, 17:16 PM -
COST-EFFECTIVENESS ANALYSIS OF TEPROTUMOMAB VERSUS BEST SUPPORTIVE CARE FOR ACTIVE MODERATE -TO-SEVERE THYROID EYE DISEASE IN FRANCE
Aug 11, 2026, 17:16 PM -
WHEN THE SILENT KILLER SPEAKS LOUDLY: HYPERTENSION'S HIDDEN IMPACT ON WORKERS' COMPENSATION CLAIMS
Aug 11, 2026, 17:16 PM -
COMPARISON OF PATIENT CHARACTERISTICS AND FIRST-LINE TREATMENT PATTERNS IN METASTATIC NSCLC: US AND FINLAND COHORTS TO INFORM OVERALL SURVIVAL TRANSPORTABILITY ANALYSES
Aug 11, 2026, 17:16 PM -
AI-ENHANCED PHARMACOVIGILANCE COMPLEMENTING RCTS TO ADVANCE THE LANDSCAPE OF SERIOUS ADVERSE EVENTS ASSOCIATED WITH IMMUNE CHECKPOINT INHIBITORS IN HEPATOCELLULAR CARCINOMA
Aug 11, 2026, 17:16 PM -
EARLY ECONOMIC EVALUATION OF ADJUNCTIVE BLOOD-BRAIN BARRIER MODULATION IN MELANOMA BRAIN METASTASES: A UK NHS PERSPECTIVE
Aug 11, 2026, 17:16 PM -
DEVELOPMENT AND VALIDATION OF A VARIABLE-BASED AI PROMPT FRAMEWORK FOR AUTOMATED GENERATION OF UK NICE DOSSIER SECTIONS: A MULTI-DRUG SOURCE FIDELITY EVALUATION
Aug 11, 2026, 17:16 PM -
IMPACT OF TREATMENT STATUS ON EQ-5D-5L UTILITIES IN ALPHA-MANNOSIDOSIS: A VIGNETTE STUDY
Aug 11, 2026, 17:16 PM -
UNLOCKING CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) DISEASE STAGE IN REAL-WORLD DATA: CLINICAL NOTES AS THE PRIMARY SOURCE OF RAI AND BINET STAGING INFORMATION USING NORSTELLALINQ
Aug 11, 2026, 17:16 PM -
EPIDEMIOLOGY, DIAGNOSIS AND TREATMENT OF CHRONIC SPONTANEOUS URTICARIA IN TURKIYE: RESULTS OF A DELPHI PANEL
Aug 11, 2026, 17:16 PM -
ONE SIZE FITS ALL? RARE DISEASES AND ADVANCED THERAPIES UNDER THE EU JOINT CLINICAL ASSESSMENT FRAMEWORK
Aug 11, 2026, 17:16 PM -
GENE THERAPY PREFERENCES: AN INTERVIEW STUDY WITH PEOPLE WITH CYSTIC FIBROSIS AND THEIR CAREGIVERS
Aug 11, 2026, 17:16 PM -
QUANTIFYING PREFERENCES FOR TYPE 2 DIABETES TREATMENTS AMONGST INDIVIDUALS IN ITALY: A DISCRETE CHOICE EXPERIMENT
Aug 11, 2026, 17:16 PM -
CLINICAL AND ECONOMIC IMPACT OF CARDIOVASCULAR AND CEREBROVASCULAR COMORBIDITIES IN MENOPAUSAL WOMEN WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS IN SPAIN
Aug 11, 2026, 17:16 PM -
ANALYSIS OF GLYCEMIC CHANGES AND RISK FACTORS FOR HYPERGLYCEMIA BY MECHANISMS OF IMMUNE CHECKPOINT INHIBITORS
Aug 11, 2026, 17:16 PM
